The global hepatitis diagnostic test market size was valued at USD 3.9 billion in 2016 and is expected to grow at a CAGR of 6.5% over the forecast period. Rising prevalence of hepatitis diagnostics is primarily diving the growth of the global market.
A data published by the World Health Organization (WHO) states that the hepatitis is the main reason for liver cancer which accounts for approximately 80% of all the liver cancer cases reported worldwide and around 1.4 million deaths annually. Additionally, the report states that around 300 chronic cases are registered globally. Considering, high prevalence of the disease driving the demand for advanced diagnostic tools.
Increasing awareness regarding the disease, and its symptoms is creating the demand for detection of Hepatitis. In addition, constantly rising awareness regarding commercially available advanced products is fueling the market growth.
Paradigm shift from conventional tools to molecular diagnosis has increased the efficiency of procedures and also has lowered the turnaround time. Molecular diagnostics involves genetic tests to confirm the exact strain of causative virus. The nucleic acid assays used include HCV RNA and HBV DNA analysis tests. Hence, the availability of such advanced detection techniques is spurring the overall market growth.
The dominance of the blood tests segment is attributed to the large test volume as they are the 1st line detection tests for hepatitis diagnostics. However, imaging tests are performed as a supportive detection tests for the confirmation of liver inflammation. Whereas, in chronic conditions, liver biopsies are performed in order to confirm the exact viral strain. Biopsies are also known to aid detection of cancerous cells in liver post hepatitis infection.
Liver function tests are the first line detection for the liver diseases which is expected to drive the growth of the segment significantly over the forecast period. Liver function tests are expected to dominate the blood tests market throughout the forecast period.
In addition, immunoassays are used to detect the presence of specific virus in the sample with the help of antibody and antigens. Furthermore, techniques such as RIBA, PCR system, ELISA, and CLIA are used to perform immunoassays which are not affordable to all the patients across the globe.
North America dominated the market with the largest revenue share in 2016. Availability of advanced diagnostic tools and high awareness regarding these products are the key factors driving the growth of the market in North America.
The accelerated growth in the Canadian market can be attributed to the initiatives of the government and non-government organizations. For instance, The Public Health Agency of Canada organized the World Hepatitis Day in order to increase the awareness regarding hepatitis detection. Thereby, leading to demand surge for hepatitis detection in the country.
The global Hepatitis report by the WHO states that the prevalence of the Type B of the disease in South East Asia is approximately 0.7%. It also states that the incidence rate of HCV infection in 1,000,000 people is 14.7. The WHO also states a few reasons such as unprotected sex, vital spread of infections, and transfer for body fluids from infected individuals are expected to increase the burden of the disease in the Asia Pacific region. Consequently, the demand for detection techniques is anticipated to grow significantly in Asia Pacific in the near future.
The key players of the market include Siemens Ag, F. Hoffmann La-Roche, Abbott Laboratories; DiaSorin S.p.A; bioMeriuex, MedMira, Inc.; Hologic, Inc.; Danaher Corporation, and Bio Rad Laboratories, etc. Strategies such as mergers and acquisitions, partnerships with small/local players are widely adopted by key players to sustain the competition.
|
Attribute |
Details |
|
Base year for estimation |
2016 |
|
Actual estimates/Historical data |
2014 - 2015 |
|
Forecast period |
2017 - 2025 |
|
Market representation |
Revenue in USD Million & CAGR from 2017 to 2025 |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America& MEA |
|
Country scope |
U.S., Canada, UK, Germany, China, Japan, Brazil, Mexico, & South Africa |
|
Report coverage |
Revenue, company share, competitive landscape, growth factors, trends |
|
15% free customization scope (equivalent to 5 analysts working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the hepatitis diagnostics market report on the basis of test types, and region:
Diagnostic Tests Outlook (Revenue, USD Million; 2014 - 2025)
Blood tests
Liver function tests
Immunoassays
Nucleic Acid Tests
Imaging Tests
Liver Biopsy
Regional Outlook (Revenue, USD Million; 2014 - 2025)
North America
U.S.
Canada
Europe
Germany
UK
Asia Pacific
China
Japan
Latin America
Mexico
Brazil
MEA
South Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
